drugset / Trial / NCT03222622

Study of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis

NCT03222622

RandomizedParallel-groupDouble-blindTreatment

Summary

This is a phase II study to evaluate the efficacy and safety of Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis.

Timeline

Start
2017-11-29
Primary completion
2018-08-15
Completion
2018-10-26

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotinib Small molecule 1 % Topical
Subject Icotinib Small molecule 2 % Topical
Subject Icotinib Small molecule 4 % Topical

Indications